Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: This paper proposes an innovative recursive filtering algorithm for nonlinear microseismic systems with signal attenuation. Firstly, the microseismic wavelet and nearby noise are modeled as ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...

The last time I wrote about Recursion Pharmaceuticals (RXRX) it was with respect to a Seeking Alpha article entitled "Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245". In ...

Abstract: In recent years, the spotlight of research in the adaptive learning era has turned toward distributed adaptive filtering algorithms for sparse systems over ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

Recursion and Exscientia, two artificial intelligence firms, on Thursday announced that they would combine, betting their complementary skills in technology-based drug discovery will lead to faster ...

Scientists in Spain have implemented recursive least squares (RLS) algorithms for anomaly detection in PV systems and have found they can provide “more realistic and meaningful assessment” than ...